Brand name authorized in: United States
The drug ADHANSIA XR contains one active pharmaceutical ingredient (API):
Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space.
This drug has been assigned below unique identifiers within the countries it is being marketed: